Patents by Inventor Dowdy Jackson

Dowdy Jackson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AURISTATIN-RELATED COMPOUNDS, CONJUGATED AURISTATIN-RELATED COMPOUNDS, AND METHODS OF USE THEREOF
    Publication number: 20230071763
    Abstract: The invention relates generally to novel compounds of the auristatin family, to novel linkers for coupling a payload to another molecule, such a target-binding molecule, to novel linker-toxin molecules, and to novel antibody molecules that allow controlled, site-specific conjugation.
    Type: Application
    Filed: January 6, 2021
    Publication date: March 9, 2023
    Inventors: Siew Schleyer, Brian A. Mendelsohn, Pia Challita-Eid, Dowdy Jackson, Christopher Kemball
  • ANTI-SLC34A2 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF
    Publication number: 20230073692
    Abstract: The invention relates generally to antibodies that bind SLC34A2, and methods of making and using these anti-SLC34A2 antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: January 6, 2021
    Publication date: March 9, 2023
    Inventors: Dowdy Jackson, Yuriy Shostak, Christopher Kemball, Pia Challita-Eid
  • SYNERGISTIC TREATMENT OF CELLS THAT EXPRESS EPHA2 AND ERBB2
    Publication number: 20100254996
    Abstract: The present invention relates to methods of treating hyperproliferative cells that express EphA2 and ErbB2. The present invention further relates to methods of selecting patient populations for treatment methodologies.
    Type: Application
    Filed: June 16, 2008
    Publication date: October 7, 2010
    Applicants: MEDIMMUNE, LLC, VANDERBILT UNIVERSITY
    Inventors: Dana Brantley-Sieders, Jin Chen, Elizabeth Bruck-Heimer, Dowdy Jackson